The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.